0

Epinephrine Autoinjector Market by Dosage, End-user, and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 151
  • SKU: IRTNTR43297
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The epinephrine autoinjector market is estimated to grow at a CAGR of 9.68% between 2022 and 2027 and size of the market is forecast to increase by USD 2,014.33 million.The reports include a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 15 vendors along with historical market analysis from 2017 to 2021.The global incidence of food item, food additive, latex, dust, and related anaphylaxis allergies is on the rise. Approximately 30-35% of the world's population is diagnosed with an allergy each year. This trend, initially observed in the UK, Europe, and the US, has now become prevalent in all developed countries. The development of an allergy may be influenced by various factors, including exposure to allergens such as peanuts, pollen, pet dander, skin irritants such as household cleaners, certain fabrics, or soaps, stress, dry skin, and infections.

This report extensively covers market segmentation by dosage (0.30gm, 0.15gm, and 0.50gm), end-user (hospitals, clinics, and homecare), and geography (North America, Europe, Asia, and Rest of World (ROW)). 

What will be the size of the Epinephrine Autoinjector Market During the Forecast Period?

Epinephrine Autoinjector Market Size

To learn more about this report, Download Report Sample

Who are the Major Epinephrine Autoinjector Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Key Offering - The Shionogi and Co. Ltd. company offers an epinephrine autoinjector namely, AUVI-Q as its key offering. The company operates in a single business segment related to prescription drugs involving research and development, purchasing, manufacturing, distribution and related businesses for prescription drugs.

Key Offering - The Adamis Pharmaceuticals company offers epinephrine auto-injectors such as SYMJEPI 0.15mg, and SYMJEPI 0.3mg.The company business segment includes without limitation out-licensing the Company FDA approved products.

The report also includes detailed analyses of the competitive landscape of the market and information about 10 market vendors, including:

  • Adamis Pharmaceuticals Corp.
  • ALK Abello AS
  • Amneal Pharmaceuticals Inc.
  • BIOPROJET
  • Crossject
  • Halozyme Therapeutics Inc.
  • kaleo Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Windgap Medical Inc.
  • Bausch Health Co Inc.

Epinephrine Autoinjector Market: Key Drivers, Trends, Challenges, and Customer Landscape

The marketing strategies have a notable driving the market growth, although factors such as product recall and regulatory issues may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Epinephrine Autoinjector Market Driver

Over the past five years, market players have implemented various strategies to expand their product offerings and strengthen their presence in the global epinephrine autoinjector market. These strategies include mergers and acquisitions and technology partnerships. For instance, ALK Abello is conducting clinical trials to demonstrate the efficacy of Jext, which is equivalent to Viatris EpiPen. Prior to the recall of Auvi-Q and Allerject, Sanofi also utilized various marketing tactics to increase its market share. By employing various strategies, vendors aim to encourage end-users to use epinephrine autoinjectors and mitigate the negative impact of the high cost of these products.

Key Epinephrine Autoinjector Market Trend

Tentative product launches are the primary trend in the market. The US market is forecasted to witness a number of product launches during the forecast period due to the increased government pressure on the FDA to approve more generic products of epinephrine autoinjectors. For instance, after the price surge of Viatris EpiPen, the US Governor, Margaret Wood Hassan, appealed to the FDA to consider and approve other alternatives to Viatris EpiPen, including generic epinephrine autoinjectors. The companies like Bausch Health, Lincoln Medical, and ALK Abello, which have substantial shares in the European market, may consider entering the US market after this US government initiative.

For instance, In March 2020, Teva Pharmaceutical Industries announced the commercial launch of the AJOVY in the prefilled YpsoMate 2.25 autoinjector in the German market. This is a clinical and self-administered autoinjector for adults with moderate to severe migraines. The product can administer 2.25 ml of the drug, and it is an anti-CGRP treatment for the prevention of migraines with monthly and quarterly dosing options. Hence, product launches and approvals for new products are expected to positively impact market growth during the forecast period.

Key Epinephrine Autoinjector Market Challenge

Product recalls and regulatory issues are the major challenge impeding the market growth. The market has continuously faced hindrances owing to periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Viatris monopoly.

Additionally, after Sanofi's exit, Viatris monopolized the US market, partially due to the FDA's limited approval of other products and partially because their only competitor, Impax Laboratories (now Amneal Pharmaceuticals), did not have an automated manufacturing facility of generic Adrenaclick supply. Since the accuracy of epinephrine dose delivery is very crucial during emergency anaphylactic shock, vendors are not left with any option other than a product recall. Hence, not many vendors prefer to enter the market, which negatively impacts market growth.

Key Epinephrine Autoinjector Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Epinephrine Autoinjector Market Share by Geography

Global Epinephrine Autoinjector Market Customer Landscape

Parent Market Analysis

The reports categorize the global epinephrine autoinjector market as a part of the global healthcare equipment market. The parent, global healthcare equipment market covers products and companies engaged in research and development (R&D) of a variety of product categories, including capital equipment, instruments, implants, accessories, and consumables that are used for the diagnosis, monitoring, and treatment of various diseases. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

What is the Fastest-Growing Segment in the Epinephrine Autoinjector Market?

The market share growth of the 0.30gm segment will be significant during the forecast period. The global epinephrine autoinjector market by 0.30gm dosage is expected to witness the highest growth due to the rise in volume sales of generic epinephrine autoinjectors. Amneal Pharmaceuticals Inc. generic Adrenaclick has already gained popularity after the sudden price hike by Viatris in the US market. The adoption of generic epinephrine autoinjectors is expected to increase further once Viatris generic EpiPen gets launched in the market. In the European market, with the higher availability of different brands, Viatris share may decrease, which may hamper its market growth.

Epinephrine Autoinjector Market Size

Get a glance at the market contribution of various segments Request a PDF Sample

The 0.30gm segment was valued at USD 1,782.04 million in 2017 and continues to grow until 2021. The gradual price hike of Viatris year-wise, after the periodic exit of its leading competitors from the market, led researchers from universities and emerging companies to focus on developing an alternative to EpiPen. Hence, with the latest developments, the growth of the market by 0.30gm dosage is assured.

Which are the Key Regions for the Epinephrine Autoinjector Market?

Epinephrine Autoinjector Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 46% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America was the leading revenue contributor to the global epinephrine autoinjector market in 2020, owing to high revenue generation in the US and Canadian markets. The lack of FDA approvals and strict FDA regulations for not considering any other generic epinephrine autoinjectors as an equivalent to Viatris EpiPen eased the way for Viatris monopoly in the booming US market. Furthermore, the epinephrine market in the US is projected to show significant growth during the forecast period owing to the higher adoption rates of generic epinephrine autoinjectors among individuals. With the launch of the generic EpiPen, the sales volume of epinephrine autoinjectors rose in the US market, which further drove the market growth. 

Covid Recovery

The outbreak of COVID-19 negatively impacted the growth of the market in the first half of 2020. However, the demand for autoinjectors increased in the last quarter of 2020 as lockdowns were lifted considerably for healthcare facilities in almost all countries. As a result, the market witnessed more demand for devices that can allow both administration and monitoring at home. Medication practices were geared up for self-administration among patients. 

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by dosage (0.30gm, 0.15gm, and 0.50gm), end-user (hospitals, clinics, and homecare), and geography (North America, Europe, Asia, and Rest of World (ROW)).

  • Dosage Outlook (USD Million, 2017 - 2027)
    • 0.30gm
    • 0.15gm
    • 0.50gm
  • End-user Outlook (USD Million, 2017 - 2027)
    • Hospitals
    • Clinics
    • Homecare
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW))
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Epinephrine Autoinjector Market Scope

Report Coverage

Details

Page number

151

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 9.68%

Market growth 2023-2027

USD 2,014.33 million

Market structure

Concentrated

YoY growth (%)

8.07

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 46%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Shionogi and Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Windgap Medical Inc., and Bausch Health Co Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Epinephrine Autoinjector Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the epinephrine autoinjector market between 2023 and 2027
  • Precise estimation of the epinephrine autoinjector market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of epinephrine autoinjector market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Dosage
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global epinephrine autoinjector market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global epinephrine autoinjector market 2017 - 2021 ($ million)
    • 4.2 Dosage Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Dosage Segment 2017 - 2021 ($ million)
    • 4.3 End-user Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Dosage

    • 6.1 Market segments
      • Exhibit 30: Chart on Dosage - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Dosage - Market share 2022-2027 (%)
    • 6.2 Comparison by Dosage
      • Exhibit 32: Chart on Comparison by Dosage
      • Exhibit 33: Data Table on Comparison by Dosage
    • 6.3 0.30gm - Market size and forecast 2022-2027
      • Exhibit 34: Chart on 0.30gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on 0.30gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on 0.30gm - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on 0.30gm - Year-over-year growth 2022-2027 (%)
    • 6.4 0.15gm - Market size and forecast 2022-2027
      • Exhibit 38: Chart on 0.15gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on 0.15gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on 0.15gm - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on 0.15gm - Year-over-year growth 2022-2027 (%)
    • 6.5 0.50gm - Market size and forecast 2022-2027
      • Exhibit 42: Chart on 0.50gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on 0.50gm - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on 0.50gm - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on 0.50gm - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Dosage
      • Exhibit 46: Market opportunity by Dosage ($ million)

    7 Market Segmentation by End-user

    • 7.1 Market segments
      • Exhibit 47: Chart on End-user - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on End-user - Market share 2022-2027 (%)
    • 7.2 Comparison by End-user
      • Exhibit 49: Chart on Comparison by End-user
      • Exhibit 50: Data Table on Comparison by End-user
    • 7.3 Hospitals and clinics - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
    • 7.4 Homecare - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Homecare - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by End-user
      • Exhibit 59: Market opportunity by End-user ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 61: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 62: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 63: Chart on Geographic comparison
      • Exhibit 64: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 93: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 101: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 104: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 105: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 106: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 107: Matrix on vendor position and classification
            • 12.3 Adamis Pharmaceuticals Corp.
              • Exhibit 108: Adamis Pharmaceuticals Corp. - Overview
              • Exhibit 109: Adamis Pharmaceuticals Corp. - Business segments
              • Exhibit 110: Adamis Pharmaceuticals Corp. - Key offerings
              • Exhibit 111: Adamis Pharmaceuticals Corp. - Segment focus
            • 12.4 ALK Abello AS
              • Exhibit 112: ALK Abello AS - Overview
              • Exhibit 113: ALK Abello AS - Product / Service
              • Exhibit 114: ALK Abello AS - Key offerings
            • 12.5 Amneal Pharmaceuticals Inc.
              • Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus
            • 12.6 Bausch Health Co Inc.
              • Exhibit 120: Bausch Health Co Inc. - Overview
              • Exhibit 121: Bausch Health Co Inc. - Business segments
              • Exhibit 122: Bausch Health Co Inc. - Key news
              • Exhibit 123: Bausch Health Co Inc. - Key offerings
              • Exhibit 124: Bausch Health Co Inc. - Segment focus
            • 12.7 BIOPROJET
              • Exhibit 125: BIOPROJET - Overview
              • Exhibit 126: BIOPROJET - Product / Service
              • Exhibit 127: BIOPROJET - Key offerings
            • 12.8 Crossject
              • Exhibit 128: Crossject - Overview
              • Exhibit 129: Crossject - Product / Service
              • Exhibit 130: Crossject - Key offerings
            • 12.9 Halozyme Therapeutics Inc.
              • Exhibit 131: Halozyme Therapeutics Inc. - Overview
              • Exhibit 132: Halozyme Therapeutics Inc. - Product / Service
              • Exhibit 133: Halozyme Therapeutics Inc. - Key offerings
            • 12.10 kaleo Inc.
              • Exhibit 134: kaleo Inc. - Overview
              • Exhibit 135: kaleo Inc. - Product / Service
              • Exhibit 136: kaleo Inc. - Key offerings
            • 12.11 Shionogi and Co. Ltd.
              • Exhibit 137: Shionogi and Co. Ltd. - Overview
              • Exhibit 138: Shionogi and Co. Ltd. - Product / Service
              • Exhibit 139: Shionogi and Co. Ltd. - Key offerings
            • 12.12 Teva Pharmaceutical Industries Ltd.
              • Exhibit 140: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 141: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 142: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 143: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 144: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.13 Viatris Inc.
              • Exhibit 145: Viatris Inc. - Overview
              • Exhibit 146: Viatris Inc. - Business segments
              • Exhibit 147: Viatris Inc. - Key offerings
              • Exhibit 148: Viatris Inc. - Segment focus
            • 12.14 Windgap Medical Inc.
              • Exhibit 149: Windgap Medical Inc. - Overview
              • Exhibit 150: Windgap Medical Inc. - Product / Service
              • Exhibit 151: Windgap Medical Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 152: Inclusions checklist
                • Exhibit 153: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 154: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 155: Research methodology
                • Exhibit 156: Validation techniques employed for market sizing
                • Exhibit 157: Information sources
              • 13.5 List of abbreviations
                • Exhibit 158: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Epinephrine Autoinjector market growth will increase by $2014.33 million during 2023-2027.
              The epinephrine autoinjector market is expected to grow at a CAGR of 9.68% during 2023-2027.
              Technavio has segmented the epinephrine autoinjector market by usage (0.30gm, 0.15gm, and 0.50gm) ,end-user (Hospitals, clinics, Homecare, and ROW) , and geography (North America, Europe, Asia, and Rest of World (ROW)).
              Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Shionogi and Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Windgap Medical Inc., Bausch Health Co Inc. are a few of the key vendors in the epinephrine autoinjector market.
              North America will register the highest growth rate of 46.06% among the other regions. Therefore, the epinephrine autoinjector market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the epinephrine autoinjector market growth are:
              • Increasing prevalence of allergies
              • Tentative product launches
              The epinephrine autoinjector market vendors should focus on grabbing business opportunities from the 0.30gm segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>